3 Oncology, Medical University Clinic, Kantonsspital Baselland, Liestal …Journal of Nuclear Medicine (subscription)The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to 177Lu-DOTA-rituximab in…
Research and Markets: Novel Drugs to Drive Arthritis MarketWall Street Journal (press release)Other well-established therapies have also been allowed to keep their patents, including second-line RA treatment Actemra. However, patents are due to expire …
|
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …
The Herald | HeraldOnline.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
MedscapeEntecavir May Prevent HBV Reactivation in Lymphoma PatientsMedscapeAntiviral prophylaxis with entecavir might help prevent rituximab-associated hepatitis B virus (HBV) reactivation in patients with lymphoma and resolved hepatitis B, according t…
MedscapeObinutuzumab Active in Elderly Chronic Lymphocytic LeukemiaMedscapeObinutuzumab is a new monoclonal antibody directed against CD20, which is also targeted by rituximab (Rituximab, Genentech/Roche). However, obinutuzumab is a humanized antibody …
|
Complication risk not related to timing between rituximab, surgery for RA patients
Healio Jérémie Sellam, MD, PhD, of the department of rheumatology, University of Paris VI, and colleagues studied 133 patients with rheumatoid arthritis (RA; median age, 59 years) who underwent 140 procedures within 1 year of rituximab (RTX) infusion and had … |
|
Clinical Data Evaluating Oral REVLIMID ® Either with Rituximab or Following …
EON: Enhanced Online News (press release) BOUDRY, Switzerland–(EON: Enhanced Online News)–Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the use of REVLIMID® (lenalidomide) either with rituximab or following a … |
|
Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non …
EON: Enhanced Online News (press release) “The increasing volume of clinical evidence evaluating combinations utilizing REVLIMID plus rituximab provide us powerful insight into the potential of antibody-dependent cellular cytotoxicity in lymphomas, and the potential of these novel combinations … |
|
Celgene Announces Results of Two Studies Evaluating Combo of Revlimid …
Benzinga Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID^® (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas … Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non …EON: Enhanced Online News (press release) |
|
Celgene (CELG) Presents Data on Two REVLIMID + Rituximab Studies
StreetInsider.com (subscription) Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas were … |